CRC

EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, April 10, 2024
Gene expression, Colorectal cancer, Partnership, Patient, Biomarker, Gold, Pivotal, Messenger, Oncology, Science, PMA, CRC, EOL, Marketing, FDA, Physician, Quest Diagnostics, Vaccine

ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million

Key Points: 
  • ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million
    BERKELEY, US – MAINZ, Germany – April 9, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023.
  • “This past fiscal year represented an important period of progress for the Company highlighted by reporting results from our groundbreaking ColoFuture and eAArly DETECT studies which demonstrated extraordinary statistical significance for colorectal cancer (CRC) detection and advanced adenomas, a type of pre-cancerous polyp which are considered precursors to colorectal cancer” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • Final preparations for Pivotal FDA PMA clinical trial (ReconAAsense) evaluating gold standard self-administered CRC test - on track to commence patient enrollment in 2024.
  • Established commercial operations in major markets including Spain, Poland, Romania, Portugal, Israel, and the UK.

RETRANSMISSION: Canter Resources Expands the Columbus Project to Approximately 30,000 Acres to Cover West Trending Lithium Brine Target

Retrieved on: 
Monday, April 8, 2024
Lithium, OTC Markets Group, 3D, Large Binocular Telescope, CRC, Data, Canter and gallop

The full surface sampling dataset, shown in Figure 1, includes highly anomalous lithium ("Li") values along the Company's previous western boundary and beyond.

Key Points: 
  • The full surface sampling dataset, shown in Figure 1, includes highly anomalous lithium ("Li") values along the Company's previous western boundary and beyond.
  • "Our team sees tremendous potential at Columbus and we are excited to get underway with Geoprobe drilling, which will commence imminently."
  • Watch: Video animation highlighting Columbus surface and 3D model results, newly staked ground and substantial Li-brine target with initial drill locations.
  • Watch Video Here >
    The 3D modeling has been instrumental in revealing the expansive potential within the Columbus Project area.

Canter Resources Expands the Columbus Project to Approximately 30,000 Acres to Cover West Trending Lithium Brine Target

Retrieved on: 
Monday, April 8, 2024
Lithium, OTC Markets Group, 3D, Large Binocular Telescope, CRC, Data, Canter and gallop

The full surface sampling dataset, shown in Figure 1, includes highly anomalous lithium ("Li") values along the Company's previous western boundary and beyond.

Key Points: 
  • The full surface sampling dataset, shown in Figure 1, includes highly anomalous lithium ("Li") values along the Company's previous western boundary and beyond.
  • "Our team sees tremendous potential at Columbus and we are excited to get underway with Geoprobe drilling, which will commence imminently."
  • Watch: Video animation highlighting Columbus surface and 3D model results, newly staked ground and substantial Li-brine target with initial drill locations.
  • Watch Video Here >
    The 3D modeling has been instrumental in revealing the expansive potential within the Columbus Project area.

Canter Resources Selects Cascade for Shallow Geoprobe Drilling at Columbus

Retrieved on: 
Wednesday, March 27, 2024
Lithium, OTC Markets Group, Project, Option, News, National instrument, QP, Puzzle Lake, Mineral, CRC, Technical advisor, Data, Canter and gallop, Oil

Vancouver, British Columbia--(Newsfile Corp. - March 27, 2024) - Canter Resources Corp. (CSE: CRC) (OTC Pink: CNRCF) (FSE: 6O1) ("Canter" or the "Company") is pleased to report that the Company has selected Cascade Drilling L.P. to complete shallow Geoprobe drilling at the Columbus Lithium-Boron Project ("Columbus" or the "Project"), located near Tonopah, Nevada.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 27, 2024) - Canter Resources Corp. (CSE: CRC) (OTC Pink: CNRCF) (FSE: 6O1) ("Canter" or the "Company") is pleased to report that the Company has selected Cascade Drilling L.P. to complete shallow Geoprobe drilling at the Columbus Lithium-Boron Project ("Columbus" or the "Project"), located near Tonopah, Nevada.
  • The Geoprobe drill campaign has been designed to collect both sediment and water samples from depths ranging between 3-30 metres (approximately 10-100 feet) below surface.
  • "The shallow Geoprobe program compliments our upcoming exploration well drilling as part of Phase I work and will provide us with another valuable dataset at Columbus," stated Joness Lang, CEO of Canter Resources.
  • In addition to characterizing the interpreted shallow brine generation layer, the Geoprobe drilling will provide more structural and geochemical data from 15-45 m depths that will further inform the Company's geological model.

Canter Outlines Significant Subsurface Brine Target with Updated 3D Modeling

Retrieved on: 
Wednesday, March 20, 2024
Lithium, OTC Markets Group, Canter and gallop, 3D, CRC

The new 3D model has further refined the understanding of subsurface structures and potential lithium-bearing brine formations covering an expanded 5 by 10 kilometre ("km") target area outlined within the central part of the Columbus Lithium-Boron Project ("Columbus" or the "Project").

Key Points: 
  • The new 3D model has further refined the understanding of subsurface structures and potential lithium-bearing brine formations covering an expanded 5 by 10 kilometre ("km") target area outlined within the central part of the Columbus Lithium-Boron Project ("Columbus" or the "Project").
  • "Most importantly, the 3D rendering of HSAMT resistivity shells shows a very compelling brine target that our team is excited to begin testing with Geoprobe and exploration well drilling during our Phase I program."
  • These highly conductive shells, indicative of brine solutions, are the focus of the Company's lithium enriched targeting efforts.
  • The priority target area is well within the Company's 23,000-acre Columbus property package and expanding HSAMT coverage will be considered later this year.

Canter Resources Appoints New CFO, Corporate Secretary, Provides Corporate Updates and Announces Annual General Meeting Date

Retrieved on: 
Thursday, March 14, 2024
Cloud, OTC Markets Group, McMillan LLP, Tax, Growth, CFO, AGM, Head, Marketing, Suite, TSX, Annual general meeting, Streetwise, CAD, CRC, High Tide, USD, PO, Corporation, CPA

In a corresponding move, Sarah Hundal will step down from her CFO and Corporate Secretary role and support the new appointees during the transition.

Key Points: 
  • In a corresponding move, Sarah Hundal will step down from her CFO and Corporate Secretary role and support the new appointees during the transition.
  • We continue to augment the corporate group as we enter this exciting phase of growth for the Company."
  • Annual General Meeting: The Company also announces that it has set its Annual General Meeting (the "AGM") for April 25, 2024 at 10:00 am (Vancouver Time).
  • High Tide is a Vancouver-based consulting company established in 2018 that provides corporate communications and investor relations services for publicly traded companies.

Canter Secures Merritt Construction for Gravel Work and Drill Site Preparations

Retrieved on: 
Wednesday, March 13, 2024
Lithium, OTC Markets Group, Project, News, Transport, National instrument, QP, CRC, Technical advisor

Vancouver, British Columbia--(Newsfile Corp. - March 13, 2024) - Canter Resources Corp. (CSE: CRC) (OTC Pink: CNRCF) (FSE: 6O1) ("Canter" or the "Company") is pleased to announce that the Company has engaged Merritt Construction Inc., located in Mina, Nevada, to carry out upcoming gravel work and drill site preparations at the Columbus Lithium-Boron Project ("Columbus" or the "Project").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 13, 2024) - Canter Resources Corp. (CSE: CRC) (OTC Pink: CNRCF) (FSE: 6O1) ("Canter" or the "Company") is pleased to announce that the Company has engaged Merritt Construction Inc., located in Mina, Nevada, to carry out upcoming gravel work and drill site preparations at the Columbus Lithium-Boron Project ("Columbus" or the "Project").
  • "We are very pleased to be working with an experienced and trusted local contractor, Dick Merritt of Merritt Construction, for our upcoming gravel work and drill site preparations at Columbus," stated Joness Lang, CEO of Canter.
  • Gravel will be sourced from a Bureau of Land Management community gravel pit during the Company's Phase I exploration program.
  • In addition to further road reinforcement, Merritt Construction will return to Columbus to complete drill site and sump preparations, as well as supply and store water for the Company's initial exploration well drilling.

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Lung cancer, Survival, NSCLC, Immunotherapy, Colorectal cancer, Central nervous system, Patient, CNS, Neoplasm, AACR, PDX, Clinical trial, Pancreatic cancer, Cancer, CRC, Metastasis, Proteome, PD-1, Pharmaceutical industry

- The Phase 1/2 PROSPER clinical trial is currently evaluating FMC-376 in patients with KRASG12C cancers, regardless of prior KRAS inhibitor therapy BOSTON and SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today presented new preclinical data on its KRASG12C inhibitor, FMC-376, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. The new findings demonstrate FMC-376’s potential to overcome known mechanisms of innate and acquired resistance and in a CNS model of metastasis as a monotherapy and increase the efficacy of PD-1 immunotherapy in combination.

Key Points: 
  • “These data demonstrate FMC-376’s unmatched potential to overcome over 90 percent of known resistance mechanisms, including those cancers that have become refractory to approved KRAS inhibitors.
  • The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the resistance and lack of response seen with current KRASG12C single-acting treatments.
  • These results reinforce that FMC-376 has the potential to overcome limitations of single-acting KRASG12C inhibitors.
  • The combination of FMC-376 with an immune checkpoint inhibitor also leads to an increased response and survival in preclinical models.

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Retrieved on: 
Tuesday, April 9, 2024
Mutation, Growth, NSCLC, Colorectal cancer, RAS, Patient, Research, PDAC, Lung cancer, GTP, AACR, Clinical trial, Cancer, CRC, G13, G12, Pharmaceutical industry

This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.

Key Points: 
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
  • Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC).
  • RAS G12 mutations, such as G12D, G12V and G12C, predominate in human cancers.
  • The paper describes the discovery of RMC-6236, an oral, multi-selective inhibitor of the active GTP-bound (ON) state of both mutant and wild-type RAS.

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Breast cancer, SMARCA4, MCL, Generation, Prelude, CDK2, CLL, NSCLC, Patient, SMARCA2, Selective estrogen receptor degrader, BCL2, Cancer, AACR, CRC, BTK, CDK9, DLBCL, Pharmaceutical industry

WILMINGTON, Del., April 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting for its highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation oral CDK4/6 inhibitor.

Key Points: 
  • Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses
    Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC
    WILMINGTON, Del., April 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting for its highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation oral CDK4/6 inhibitor.
  • “These presentations demonstrate our core competencies in medicinal chemistry and cancer biology to optimize and deliver compounds to the clinic with the potential to succeed as differentiated first- and/or best-in-class new therapies,” said Andrew Combs, Ph.D., Chief Chemistry Officer at Prelude Therapeutics.
  • Peggy Scherle, Ph.D., Chief Scientific Officer at Prelude, stated, “Advancement of our second highly selective SMARCA2 degrader strengthens Prelude’s leadership position in the emerging use of SMARCA2 protein degradation as a potential treatment option for underserved patients with cancer.
  • With both a first-in-class IV SMARCA2 degrader, PRT3789, in Phase 1 clinical development and now our oral SMARCA2 degrader, PRT7732, expected to enter the clinic later this year, we believe these distinct modalities may offer new therapies for patients with SMARCA4 mutations.”
    Details on the poster presentations are as follows:
    Identified potent, selective, well-tolerated and orally bioavailable SMARCA2 degrader, PRT7732
    PRT7732 exhibits >3000-fold selectivity for SMARCA2 over SMARCA4, with low nanomolar potency in cell based assays
    Title: PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies
    PRT2527 is efficacious as monotherapy in preclinical models of DLBCL, CLL and MCL, and combines with both BTK and BCL2 inhibition to improve depth and duration of responses
    Title: The Brain Penetrant CDK4/6 Inhibitor, PRT3645, is Highly Effective in Combination with Other Targeted Therapies in Preclinical Models of Breast Cancer, CRC and NSCLC
    Next generation CDK4/6 inhibitor, PRT3645, demonstrates preclinical synergy with SERDs, as well as MEK1/2 and CDK2 inhibition